Two papers by our researchers (research at Takeda Pharmaceutical Sciences) were featured in the August issue of Synfacts, a professional journal that selects and introduces outstanding research from among the latest papers on synthetic organic chemistry published in journals.
Journal: synfacts 2019; 15(08): 0843
Paper: Org. Process Ress. Dev. 2019, 23, 535-547
Title: Synthesis of a TAK-480 Fragment
Authors: Masatoshi Yamada, Hirotsugu Usutani, Tatsuya Ito, and Mitsuhisa Yamano（Chemical R&D Division）
Journal: synfacts 2019; 15(08): 0844
Paper: Org. Process Ress. Dev. 2019, 23, 484-492
Title: Synthesis of TAK-063
Authors: Akihiro Suzuki, Naohiro Fukuda, Takeshi Kajiwara, and Tomomi Ikemoto （Chemical R&D Division）
The technology and experience in API process research and development, such as the high-profile paper, is one of SPERA PHARMA’s strengths. We contribute to the creation of new pharmaceutical products for our customers through our accumulated synthesis technologies and knowledge continuously.
SPERA PHARMA is committed to contributing to the rapid creation of pharmaceutical products by solving the challenges faced by our customers through further refinement based on our cultivated technology and experience.